Yale and Mayo Clinic team up to study opioid prescribing

1 August 2019
opioid_us_medicines_large

Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the US Food and Drug Administration (FDA) to study patients’ experiences with pain and use of opioids.

The project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI), which involves all three parties. The study will be conducted in collaboration with Regional Health of Rapid City, and University of Alabama at Birmingham.

"We will be able to better understand the safeguards that need to be put in place to protect the public"It is hoped that the project will generate real-world evidence that can be used to better understand how patients use opioids for acute pain, and for how long opioids are needed, in order to inform guidelines and promote safer prescribing practices that will help to confront the addiction crisis in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical